Heterozygote advantage at HLA class I and II loci and reduced risk of colorectal cancer
Tsai Y, et al.
Frontiers in Immunology
November 2023
Authors and Affiliates
Ya-Yu Tsai 1, Chenxu Qu 2, Joseph D Bonner 3, Rebeca Sanz-Pamplona 4 5 6 7, Sidney S Lindsey 3, Marilena Melas 8, Kevin J McDonnell 3, Gregory E Idos 3, Christopher P Walker 3, Kevin K Tsang 3, Diane M Da Silva 2, Ferran Moratalla-Navarro 4 5 6 9, Asaf Maoz 10, Hedy S Rennert 11, W Martin Kast 2, Joel K Greenson 12, Victor Moreno 4 5 6 9, Gad Rennert 11, Stephen B Gruber 3, Stephanie L Schmit 1 13;
1Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH, United States.
2Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, United States.
3Center for Precision Medicine, City of Hope National Medical Center, Duarte, CA, United States.
4Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain.
5ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain.
6Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP), Madrid, Spain.
7Hospital Universitario Lozano Blesa, Aragon Health Research Institute (IISA), ARAID Foundation, Aragon Government, Zaragoza, Spain.
8Molecular Diagnostics, New York Genome Center, New York, NY, United States.
9Department of Clinical Sciences, Faculty of Medicine and Health Sciences and Universitat de Barcelona Institute of Complex Systems (UBICS), University of Barcelona, Barcelona, Spain.
10Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, United States.
11B. Rappaport Faculty of Medicine, Technion and the Association for Promotion of Research in Precision Medicine (APRPM), Haifa, Israel.
12Department of Pathology, University of Michigan, Ann Arbor, MI, United States.
13Population and Cancer Prevention Program, Case Comprehensive Cancer Center, Cleveland, OH, United States.